Glass House Brands (GLAS) Gains from Investment Securities (2021 - 2026)
Glass House Brands' (GLAS) quarterly Gains from Investment Securities came in at -$409000.0 in Q1 2026, down 123.6% year-on-year from $1.7 million in Q1 2025, and down 1236.11% on a QoQ basis from $36000.0 in Q3 2025.
Glass House Brands (GLAS) Gains from Investment Securities (2021 - 2026) Analysis & Trends
Glass House Brands (GLAS) has 6 years of Gains from Investment Securities data on file, last reported at -$409000.0 in Q1 2026.
- On a quarterly basis, Gains from Investment Securities fell 123.6% year-over-year to -$409000.0 in Q1 2026; TTM through Mar 2026 was $1.7 million, a 60.92% increase from a year earlier, with the FY2022 full-year figure at $186107.0, up 100.0% from the prior year.
- Gains from Investment Securities for Q1 2026 stood at -$409000.0, down from $36000.0 in the prior quarter.
- Over the last five years, Gains from Investment Securities for GLAS reached as high as $31.1 million in Q3 2022 and fell as low as -$539000.0 in Q3 2024.
- Historically, Gains from Investment Securities has averaged $3.8 million across 5 years, with a median of $182000.0 in 2025.
- Across the five-year window, Gains from Investment Securities soared 5254.33% in 2022 and slumped 769.23% in 2024, its largest moves.
- Year by year, Gains from Investment Securities stood at $586453.0 in 2022, then sank by 102.22% to -$13000.0 in 2023, then slumped by 4046.15% to -$539000.0 in 2024, then soared by 106.68% to $36000.0 in 2025, then sank by 1236.11% to -$409000.0 in 2026.
- Per Business Quant data, the three most recent Gains from Investment Securities figures were -$409000.0 in Q1 2026, $36000.0 in Q3 2025, and $328000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn |
| 10 | Glass House Brands | 873.84 Mn | 845.91 Mn | 10.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -409,000.00 |
| Mar 31, 2026 | -409,000.00 |
| Sep 30, 2025 | 36,000.00 |
| Sep 30, 2025 | 36,000.00 |
| Jun 30, 2025 | 328,000.00 |
| Jun 30, 2025 | 328,000.00 |
| Mar 31, 2025 | 1.73 Mn |
| Mar 31, 2025 | 1.73 Mn |
| Sep 30, 2024 | -539,000.00 |
| Sep 30, 2024 | -539,000.00 |
| Jun 30, 2024 | -32,000.00 |
| Jun 30, 2024 | -32,000.00 |
| Mar 31, 2024 | -113,000.00 |
| Mar 31, 2024 | -113,000.00 |
| Mar 31, 2023 | -13,000.00 |
| Mar 31, 2023 | -13,000.00 |
| Dec 31, 2022 | 586,453.00 |
| Dec 31, 2022 | 586,453.00 |
| Sep 30, 2022 | 31.12 Mn |
| Sep 30, 2022 | 31.12 Mn |